Trials / Active Not Recruiting
Active Not RecruitingNCT04225871
Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis
A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects With Generalized Myasthenia Gravis
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 200 (actual)
- Sponsor
- UCB Biopharma SRL · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The RAISE-XT study is an open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | zilucoplan (RA101495) | Daily subcutaneous (SC) injection |
Timeline
- Start date
- 2019-12-23
- Primary completion
- 2026-06-02
- Completion
- 2026-06-02
- First posted
- 2020-01-13
- Last updated
- 2026-02-27
Locations
70 sites across 10 countries: United States, Canada, France, Germany, Italy, Japan, Norway, Poland, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04225871. Inclusion in this directory is not an endorsement.